title: [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease].
abstract: OBJECTIVE
  To study the effects of memantine on cognitive and motor impairment in patients with Parkinson's disease (PD).
  
  
  METHODS
  A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control group (n = 27) conventional antiparkinsonian drug therapy alone. The cognitive and motor evaluations were assessed at pre-treatment and 12, 24 weeks post-treatment by clinical assessment, rating scales and neuropsychological tests.
  
  
  RESULTS
  At week 24 the patients in the memantine group had better MMSE (22.8 ± 1.8), ADAS-cog (18.6 ± 2.3), and UPDRS-III (34.6 ± 4.2) scales scores than those taking placebo MMSE (18.5 ± 1.7), ADAS-cog (21.9 ± 2.4), and UPDRS-III (41.2 ± 4.0). Patients treated with memantine had better improvement on the MMSE (P < 0.05), ADAS-cog (P < 0.05), and UPDRS-III (P < 0.05) scales compared with the control group by the end of study week 24.
  
  
  CONCLUSIONS
  Memantine may improve the cognitive and motor impairments of PD. And it is both safe and well-tolerated.
authors.affiliation: Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, China. liwei71@126.com
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Zhao
authors.forename: Sheng-Gang
authors.initials: SG
authors.lastname: Sun
authors.forename: Jie-Wen
authors.initials: JW
authors.lastname: Zhang
authors.forename: Ai-Qin
authors.initials: AQ
authors.lastname: Suo
authors.forename: Ming-Ming
authors.initials: MM
authors.lastname: Ma
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D008559:Memantine